NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

Altı ay boyunca karlılık: -90.84%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Verrica Pharmaceuticals Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

daha fazla ayrıntı
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 5.32
Günlük fiyat değişimi: +5.39% (0.649)
Haftalık fiyat değişimi: -1.44% (0.694)
Aylık fiyat değişimi: -44.84% (1.24)
3 ayda fiyat değişimi: -59.53% (1.69)
Altı ayda fiyat değişimi: -90.84% (7.47)
Yıllık fiyat değişimi: -90.66% (7.32)
3 yılda fiyat değişimi: -92.58% (9.22)
5 yılda fiyat değişimi: -95.78% (16.2)
10 yılda fiyat değişimi: 0% (0.684)
Yılbaşından bu yana fiyat değişimi: -44.84% (1.24)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
Toplam: 2.75

Yeterlik

İsim Anlam Seviye
ROA, % -82.1 0
ROE, % -338.99 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.6985 10
Toplam: 7.8

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -57.3 0
karlılık Ebitda, % 106.63 10
karlılık EPS, % 40.72 6
Toplam: 6.2
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
Invesco Dorsey Wright SmallCap Momentum ETF 0.07518 33.91 0.61241
iShares Micro-Cap ETF 0.00867 17.09 1.54048
iShares Russell 2000 Growth ETF 0.0017 38.04 0.6026
ProShares UltraPro Russell2000 0.00074 89.82 1.47873
ProShares Hedge Replication ETF 0.00022 5.92 1.47892
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Ted White President, CEO & Director 772.77k 1965 (60 yıllar)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 yıllar)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 yıl)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

Adres: United States, West Chester. PA, 44 West Gay Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.verrica.com